SG10201807952PA - Jak1 inhibitors for the treatment of myelodysplastic syndromes - Google Patents
Jak1 inhibitors for the treatment of myelodysplastic syndromesInfo
- Publication number
- SG10201807952PA SG10201807952PA SG10201807952PA SG10201807952PA SG10201807952PA SG 10201807952P A SG10201807952P A SG 10201807952PA SG 10201807952P A SG10201807952P A SG 10201807952PA SG 10201807952P A SG10201807952P A SG 10201807952PA SG 10201807952P A SG10201807952P A SG 10201807952PA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- myelodysplastic syndromes
- jak1 inhibitors
- jak1
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
This invention relates to the use of JAK1 selective inhibitors, particularly pyrrolo[2,3 - d]pyrimidin e and pyrrolo[2,3 - b]pyridin e derivatives, in the manufactur e o f m e d i c a m e n t s f o r treating myelodysplastic syndromes (MDS) . 5
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461946124P | 2014-02-28 | 2014-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201807952PA true SG10201807952PA (en) | 2018-10-30 |
Family
ID=52693052
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201607083VA SG11201607083VA (en) | 2014-02-28 | 2015-02-27 | Jak1 inhibitors for the treatment of myelodysplastic syndromes |
| SG10201807952PA SG10201807952PA (en) | 2014-02-28 | 2015-02-27 | Jak1 inhibitors for the treatment of myelodysplastic syndromes |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201607083VA SG11201607083VA (en) | 2014-02-28 | 2015-02-27 | Jak1 inhibitors for the treatment of myelodysplastic syndromes |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US20150246046A1 (en) |
| EP (1) | EP3110409B1 (en) |
| JP (1) | JP6576941B2 (en) |
| KR (1) | KR20160136323A (en) |
| CN (2) | CN106456773A (en) |
| AU (1) | AU2015222913B2 (en) |
| CA (1) | CA2940659C (en) |
| CL (1) | CL2016002144A1 (en) |
| CR (1) | CR20160449A (en) |
| CY (1) | CY1120857T1 (en) |
| DK (1) | DK3110409T3 (en) |
| EA (1) | EA201691745A1 (en) |
| ES (1) | ES2688553T3 (en) |
| HR (1) | HRP20181661T1 (en) |
| HU (1) | HUE041456T2 (en) |
| IL (1) | IL247475B (en) |
| LT (1) | LT3110409T (en) |
| MX (1) | MX2016011103A (en) |
| MY (1) | MY185392A (en) |
| PE (1) | PE20161388A1 (en) |
| PL (1) | PL3110409T3 (en) |
| PT (1) | PT3110409T (en) |
| RS (1) | RS57723B1 (en) |
| SG (2) | SG11201607083VA (en) |
| SI (1) | SI3110409T1 (en) |
| UA (1) | UA121857C2 (en) |
| WO (1) | WO2015131031A1 (en) |
| ZA (1) | ZA201606610B (en) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA98449C2 (en) | 2005-12-13 | 2012-05-25 | Инсайт Корпорейшин | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| RS53245B2 (en) | 2007-06-13 | 2022-10-31 | Incyte Holdings Corp | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| LT2432472T (en) | 2009-05-22 | 2020-02-10 | Incyte Holdings Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
| AU2011224484A1 (en) | 2010-03-10 | 2012-09-27 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
| CN103002875B (en) | 2010-05-21 | 2016-05-04 | 因塞特控股公司 | Topical formulations of JAK inhibitors |
| PE20140146A1 (en) | 2010-11-19 | 2014-02-06 | Incyte Corp | PYRROLOPYRIDINE DERIVATIVES AND PYRROLOPYRIMIDINE SUBSTITUTED WITH CYCLOBUTYL AS JAK INHIBITORS |
| AR086983A1 (en) | 2011-06-20 | 2014-02-05 | Incyte Corp | DERIVATIVES OF AZETIDINIL FENIL, PIRIDIL OR PIRAZINIL CARBOXAMIDA AS JAK INHIBITORS |
| UA111854C2 (en) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS |
| MX2015005428A (en) | 2012-11-01 | 2015-07-21 | Incyte Corp | Tricyclic fused thiophene derivatives as jak inhibitors. |
| MY191357A (en) | 2012-11-15 | 2022-06-19 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
| WO2014110574A1 (en) | 2013-01-14 | 2014-07-17 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| ME03780B (en) | 2013-01-15 | 2021-04-20 | Incyte Holdings Corp | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
| UA120162C2 (en) | 2013-03-06 | 2019-10-25 | Інсайт Холдінгс Корпорейшн | Processes and intermediates for making a jak inhibitor |
| TWI719401B (en) | 2013-05-17 | 2021-02-21 | 美商英塞特公司 | Bipyrazole derivatives as jak inhibitors |
| PT3030227T (en) | 2013-08-07 | 2020-06-25 | Incyte Corp | Sustained release dosage forms for a jak1 inhibitor |
| PE20160532A1 (en) | 2013-08-23 | 2016-05-21 | Incyte Corp | COMPOUND OF FURO CARBOXAMIDE AND TENOPYRIDINE USEFUL AS INHIBITORS OF PIM KINASES |
| PL3129021T3 (en) | 2014-04-08 | 2021-05-31 | Incyte Corporation | Treatment of b-cell malignancies by a combination jak and pi3k inhibitor |
| WO2015168246A1 (en) | 2014-04-30 | 2015-11-05 | Incyte Corporation | Processes of preparing a jak1 inhibitor and new forms thereto |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| TWI734699B (en) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Salts of a pim kinase inhibitor |
| TW201718546A (en) | 2015-10-02 | 2017-06-01 | 英塞特公司 | Heterocyclic compounds useful as PIM kinase inhibitors |
| KR101960592B1 (en) * | 2016-03-09 | 2019-03-21 | 울산대학교 산학협력단 | Composition for promoting proliferation, differentiation or anti-aging of stem cell using Janus kinase 1 inhibitor |
| KR101934107B1 (en) * | 2016-12-15 | 2018-12-31 | 가톨릭대학교산학협력단 | Composition for Predicting Survival and the Response of a Patient with Myelodysplastic Syndromes to Hypomethylating Agent |
| US11524961B2 (en) | 2017-01-23 | 2022-12-13 | Shanghai Longwood Biopharmaceuticals Co., Ltd. | JAK kinase inhibitor and preparation method and use thereof |
| CN109867676B (en) * | 2017-12-01 | 2020-10-30 | 北京普祺医药科技有限公司 | Pyrrolopyrimidine derivative compound, pharmaceutical composition and application thereof |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| KR20200129099A (en) | 2018-01-30 | 2020-11-17 | 인사이트 코포레이션 | Method for producing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidin-4-one) |
| WO2019152875A1 (en) | 2018-02-01 | 2019-08-08 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of use and manufacture |
| IL276725B2 (en) | 2018-02-16 | 2024-09-01 | Incyte Corp | Jak1 pathway inhibitors for the treatment of cytokine-related disorders |
| JP7565798B2 (en) | 2018-03-30 | 2024-10-11 | インサイト・コーポレイション | Biomarkers for Inflammatory Skin Disease |
| CN112423759A (en) | 2018-03-30 | 2021-02-26 | 因赛特公司 | Treatment of hidradenitis suppurativa with JAK inhibitors |
| SG11202010092XA (en) | 2018-04-13 | 2020-11-27 | Incyte Corp | Biomarkers for graft-versus-host disease |
| JP7431845B2 (en) * | 2018-10-31 | 2024-02-15 | インサイト・コーポレイション | Combination therapy for the treatment of blood disorders |
| CN111320633B (en) * | 2018-12-14 | 2022-09-27 | 中国医药研究开发中心有限公司 | Pyrrole/imidazo six-membered heteroaromatic ring compound and preparation method and medical application thereof |
| MA55201A (en) * | 2019-03-05 | 2022-01-12 | Incyte Corp | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CHRONIC LUNG ALLOGraft DYSFUNCTION |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| CN111358791A (en) * | 2020-03-13 | 2020-07-03 | 深圳百奥捷生物科技有限公司 | Application of JAK/STAT signal pathway phosphate inhibitor in preparation of medicine for treating DBA diseases |
| US11685731B2 (en) | 2020-06-02 | 2023-06-27 | Incyte Corporation | Processes of preparing a JAK1 inhibitor |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| EP4259131A1 (en) | 2020-12-08 | 2023-10-18 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of vitiligo |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| BR9912938B1 (en) | 1998-08-11 | 2011-06-28 | isoquinoline derivatives, composition comprising them, process for preparation and use thereof. | |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| CZ303572B6 (en) | 2000-06-28 | 2012-12-12 | Smithkline Beecham P. L. C. | Finely divided preparation and process for preparing thereof |
| CN100391958C (en) | 2001-09-19 | 2008-06-04 | 安万特医药股份有限公司 | Chemical compounds |
| CA2462657C (en) | 2001-10-30 | 2011-04-26 | Novartis Ag | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
| AR037647A1 (en) | 2002-05-29 | 2004-12-01 | Novartis Ag | USED DIARILUREA DERIVATIVES FOR THE TREATMENT OF DEPENDENT DISEASES OF THE PROTEIN KINase |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| CL2003002353A1 (en) | 2002-11-15 | 2005-02-04 | Vertex Pharma | COMPOUNDS DERIVED FROM DIAMINOTRIAZOLS, INHIBITORS D ELA PROTEINA QUINASA; PHARMACEUTICAL COMPOSITION; PREPARATION PROCEDURE; AND ITS USE OF THE COMPOUND IN THE TREATMENT OF DISEASES OF ALLERGIC DISORDERS, PROLIFERATION, AUTOIMMUNES, CONDIC |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| AR045944A1 (en) | 2003-09-24 | 2005-11-16 | Novartis Ag | ISOQUINOLINE DERIVATIVES 1.4-DISPOSED |
| US20090156602A1 (en) | 2004-11-24 | 2009-06-18 | Nigel Graham Cooke | Organic Compounds |
| WO2006067445A2 (en) | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Csf-1r kinase inhibitors |
| UA98449C2 (en) * | 2005-12-13 | 2012-05-25 | Инсайт Корпорейшин | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| JP5275371B2 (en) | 2008-03-11 | 2013-08-28 | インサイト・コーポレイション | Azetidine derivatives and cyclobutane derivatives as JAK inhibitors |
| BRPI1012159B1 (en) * | 2009-05-22 | 2022-01-25 | Incyte Holdings Corporation | Compounds derived from n-(hetero)aryl-pyrrolidine of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors, compositions pharmaceuticals comprising said compounds and uses thereof |
| AR078012A1 (en) | 2009-09-01 | 2011-10-05 | Incyte Corp | HETEROCICLIC DERIVATIVES OF PIRAZOL-4-IL-PIRROLO (2,3-D) PYRIMIDINS AS INHIBITORS OF THE QUANASA JANUS |
| AU2011224484A1 (en) * | 2010-03-10 | 2012-09-27 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
| ES2536415T3 (en) | 2010-11-19 | 2015-05-25 | Incyte Corporation | Pyrrolopyridines and heterocyclic substituted pyrrolopyrimidines as JAK inhibitors |
| PE20140146A1 (en) * | 2010-11-19 | 2014-02-06 | Incyte Corp | PYRROLOPYRIDINE DERIVATIVES AND PYRROLOPYRIMIDINE SUBSTITUTED WITH CYCLOBUTYL AS JAK INHIBITORS |
| CN103370068A (en) * | 2010-12-03 | 2013-10-23 | Ym生物科学澳大利亚私人有限公司 | Treatment of JAK2-mediated conditions |
| AR086983A1 (en) * | 2011-06-20 | 2014-02-05 | Incyte Corp | DERIVATIVES OF AZETIDINIL FENIL, PIRIDIL OR PIRAZINIL CARBOXAMIDA AS JAK INHIBITORS |
| TW201313721A (en) * | 2011-08-18 | 2013-04-01 | Incyte Corp | Cyclohexyl azetidine derivatives as JAK inhibitors |
| WO2013173720A1 (en) | 2012-05-18 | 2013-11-21 | Incyte Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| US10155987B2 (en) * | 2012-06-12 | 2018-12-18 | Dana-Farber Cancer Institute, Inc. | Methods of predicting resistance to JAK inhibitor therapy |
| MX2015005428A (en) * | 2012-11-01 | 2015-07-21 | Incyte Corp | Tricyclic fused thiophene derivatives as jak inhibitors. |
| TWI719401B (en) * | 2013-05-17 | 2021-02-21 | 美商英塞特公司 | Bipyrazole derivatives as jak inhibitors |
-
2015
- 2015-02-27 EA EA201691745A patent/EA201691745A1/en unknown
- 2015-02-27 JP JP2016554471A patent/JP6576941B2/en active Active
- 2015-02-27 LT LTEP15710994.3T patent/LT3110409T/en unknown
- 2015-02-27 DK DK15710994.3T patent/DK3110409T3/en active
- 2015-02-27 WO PCT/US2015/017963 patent/WO2015131031A1/en active Application Filing
- 2015-02-27 SI SI201530368T patent/SI3110409T1/en unknown
- 2015-02-27 SG SG11201607083VA patent/SG11201607083VA/en unknown
- 2015-02-27 PE PE2016001538A patent/PE20161388A1/en unknown
- 2015-02-27 EP EP15710994.3A patent/EP3110409B1/en active Active
- 2015-02-27 UA UAA201609815A patent/UA121857C2/en unknown
- 2015-02-27 CR CR20160449A patent/CR20160449A/en unknown
- 2015-02-27 PL PL15710994T patent/PL3110409T3/en unknown
- 2015-02-27 HU HUE15710994A patent/HUE041456T2/en unknown
- 2015-02-27 PT PT15710994T patent/PT3110409T/en unknown
- 2015-02-27 SG SG10201807952PA patent/SG10201807952PA/en unknown
- 2015-02-27 MX MX2016011103A patent/MX2016011103A/en active IP Right Grant
- 2015-02-27 ES ES15710994.3T patent/ES2688553T3/en active Active
- 2015-02-27 AU AU2015222913A patent/AU2015222913B2/en active Active
- 2015-02-27 MY MYPI2016001574A patent/MY185392A/en unknown
- 2015-02-27 KR KR1020167026668A patent/KR20160136323A/en not_active IP Right Cessation
- 2015-02-27 CN CN201580017178.XA patent/CN106456773A/en active Pending
- 2015-02-27 CN CN202010986614.7A patent/CN112494652A/en active Pending
- 2015-02-27 RS RS20181194A patent/RS57723B1/en unknown
- 2015-02-27 US US14/633,605 patent/US20150246046A1/en not_active Abandoned
- 2015-02-27 CA CA2940659A patent/CA2940659C/en active Active
-
2016
- 2016-08-24 CL CL2016002144A patent/CL2016002144A1/en unknown
- 2016-08-25 IL IL247475A patent/IL247475B/en active IP Right Grant
- 2016-09-23 ZA ZA2016/06610A patent/ZA201606610B/en unknown
-
2018
- 2018-05-15 US US15/980,052 patent/US20190111058A1/en not_active Abandoned
- 2018-10-12 HR HRP20181661TT patent/HRP20181661T1/en unknown
- 2018-11-13 CY CY181101196T patent/CY1120857T1/en unknown
-
2020
- 2020-04-03 US US16/839,972 patent/US20210069193A1/en not_active Abandoned
-
2021
- 2021-12-20 US US17/556,374 patent/US20220378791A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201807952PA (en) | Jak1 inhibitors for the treatment of myelodysplastic syndromes | |
| HK1244787A1 (en) | Novel 5 or 8-substituted imidazo [1, 5-a] pyridines as indoleamine and/or tryptophane 2, 3-dioxygenases | |
| IL254224A0 (en) | 7-substituted-5-alkyl-[1,2,4] triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors | |
| SI3107914T1 (en) | Pyrazolo(1,5-a)pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use | |
| SI3419978T1 (en) | Pyrazolo(1,5-a)pyrazin-4-yl derivatives as jak-inhibitors | |
| IL266305B (en) | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors | |
| TW201613925A (en) | Imidazopyrazines as LSD1 inhibitors | |
| HK1254809A1 (en) | Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy | |
| IL247947B (en) | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4h-pyrazolo[1,5-a][1,4]diazepine derivatives as ros1 inhibitors | |
| ZA201808257B (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| IL247948B (en) | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1h-imidazo[1,2-b]pyrazole derivatives as ros1 inhibitors | |
| HK1225723A1 (en) | Substituted imidazo[1,2-a]pyridinecarboxamides and their use | |
| IL290419B (en) | Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors | |
| IL272988A (en) | Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors | |
| GB201802644D0 (en) | Monocyclic,thieno, pyrido and pyrrolo pyrimidine compounds and methods of use and manufacture of the same | |
| IL253427A0 (en) | Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis | |
| UA107549C2 (en) | 4,7-dihydro-5-amino-3-carboxamido-6-cyano[1,2,3]triazolo[1,5-a]pyrimidine derivatives and a method for their preparation |